Journal Digest: July 8, 2026

Dermatologic Therapy | Granulomatous Dermatoses and Sarcoidosis/Sarcoid-Like Disease During Dupilumab Therapy: A Phenotype-Based Case-Level Review

A review of published case reports suggests that granulomatous inflammation occurring during dupilumab therapy is rare but encompasses a broad spectrum of clinical presentations. Investigators analyzed 18 patient-level cases from 17 reports and identified 6 phenotypes, including sarcoidosis/sarcoid-like disease (11 cases), granuloma annulare, lichenoid-granulomatous drug eruption, interstitial granulomatous dermatitis, granulomatous rosacea-like reaction, and tattoo-associated granulomatous dermatitis. In 15 of 18 cases, biopsy confirmed granulomatous inflammation. The time from dupilumab initiation to symptom onset ranged from approximately 1 month to 3 years, highlighting the need for ongoing clinical vigilance. Two cases demonstrated recurrence after drug rechallenge, strengthening the potential association with dupilumab. The authors emphasize that new granulomatous eruptions during dupilumab treatment should prompt biopsy when feasible, along with evaluation for infectious and other alternative causes, rather than automatic discontinuation of therapy. They conclude that prospective pharmacovigilance studies and patient registries are needed to better define the incidence, risk factors, and underlying mechanisms of these uncommon adverse events.¹

Journal of the European Academy of Dermatology & Venereology | Scale of Alopecia Areata Distress (SAAD-41): Initial Validation Part 2—Scoring, Preliminary Reference Values and Validity

This validation study provides additional evidence supporting the Scale of Alopecia Areata Distress (SAAD-41) as a comprehensive patient-reported outcome measure for assessing the psychosocial impact of alopecia areata (AA). Investigators surveyed 358 US adults with AA who completed the 41-item questionnaire and evaluated its scoring, reference values, and validity. SAAD-41 subdomain scores showed strong correlations with the total score, supporting the use of both overall and domain-specific assessments. Approximately 20% to 40% of participants reported clinically meaningful psychosocial distress. The total SAAD-41 score also demonstrated strong correlations with established quality-of-life and psychosocial measures, including the Dermatology Life Quality Index, Acceptance of Chronic Health Conditions Scale, and Brief Resilient Coping Scale, supporting its convergent validity. Scores differed by age, sex, self-reported disease severity, disease duration, and quality-of-life impairment. The authors conclude that SAAD-41 is a promising tool for capturing the broad psychosocial burden of AA and may help clinicians better identify and monitor patients experiencing significant emotional distress.²

International Journal of Dermatology | Updated Vitiligo Trends in the Burden of Psychiatric and Autoimmune Diseases

A large real-world cohort study found that patients with vitiligo have a higher burden of psychiatric and autoimmune comorbidities than matched controls without the disease. Using the TriNetX federated electronic health record network, investigators compared 16,569 adults with vitiligo to an equal number of matched controls. Patients with vitiligo had significantly greater odds of depression, anxiety, insomnia, and suicidal ideation, underscoring the importance of routine mental health screening in dermatology practice. In contrast, alcohol and illicit substance use disorders were not increased, and nicotine dependence was slightly less common among patients with vitiligo. Consistent with previous research, vitiligo was also strongly associated with several autoimmune diseases, including autoimmune connective tissue disorders, thyroid disease, and type 1 diabetes. These findings reinforce the need for dermatology clinicians to adopt a multidisciplinary approach to vitiligo management that includes screening for psychiatric symptoms and autoimmune comorbidities alongside treatment of skin disease.³

Clinical Case Reports | A Holistic Skin Management Approach of CTMP Improved Skin Texture in Patient With Acne Scarring: A Case Report

This case report highlights the potential benefits of a holistic CTMP (cleansing, treatment, moisturizing, and photoprotection) approach for improving acne scarring and overall skin quality. A 29-year-old man with acne scars, enlarged pores, and impaired skin barrier function underwent a 70-day protocol that combined microdroplet injections of cross-linked hyaluronic acid and botulinum toxin A with a structured daily skincare regimen and strict sun protection. By the end of treatment, objective assessments demonstrated an 11% increase in skin hydration and a 6% reduction in transepidermal water loss, indicating improved barrier function. Skin texture also improved, with a 14.5% reduction in roughness, a 14.5% increase in smoothness, and a 10% reduction in wrinkle parameters. The authors suggest that combining in-office injectable therapies with consistent skincare may enhance outcomes for patients with acne scarring. However, as this report describes a single patient with short-term follow-up, larger controlled studies are needed to confirm efficacy, durability, and optimal patient selection.⁴

Japanese Journal of Dermatology | Achieving Targeted Combined Endpoints in Patients With Atopic Dermatitis: A Real-World Study

A real-world cross-sectional study suggests that many adults with atopic dermatitis (AD) fail to achieve comprehensive treat-to-target goals despite ongoing therapy. Investigators evaluated 100 adults receiving AD treatment for at least 6 months using five treatment targets: Patient Global Assessment (PGA) ≤2, Eczema Area and Severity Index (EASI) ≤7, pruritus visual analog scale (VAS) ≤4, Patient-Oriented Eczema Measure (POEM) ≤7, and Dermatology Life Quality Index (DLQI) ≤5. Only 30% of patients met all five endpoints. Older age was associated with a greater likelihood of achieving treatment targets, while DLQI was the strongest predictor of overall treatment success. Although differences among therapies were not statistically significant, the highest proportion of patients achieving all endpoints was observed in the dupilumab group, followed by Janus kinase (JAK) inhibitors. Subgroup analyses identified patients with well-controlled skin disease but persistent quality-of-life impairment, emphasizing that symptom control alone may not reflect treatment success. The findings reinforce the importance of routinely assessing patient-reported outcomes alongside clinical disease activity when managing AD.⁵

References

1. Shanshal M, Karanasios G. Granulomatous Dermatoses and Sarcoidosis/Sarcoid-Like Disease During Dupilumab Therapy: A Phenotype-Based Case-Level Review. Dermatologic Therapy. 2026, 2212248, 8 pages, 2026. doi:10.1155/dth/2212248

2. K. Gorbatenko-Roth, M. Trinitapoli, S. Wood, I. Wallander, J. Nugent, M. Hordinsky. Scale of Alopecia Areata Distress (SAAD-41): Initial Validation Part 2—Scoring, Preliminary Reference Values and Validity. JEADV Clinical Practice. 0 (2026): 1-21. doi:10.1002/jvc2.70378

3. Verma KK, Minbaeva S, Tarbox MB, et al. Updated Vitiligo Trends in the Burden of Psychiatric and Autoimmune Diseases. Int J Dermatol. Published online July 6, 2026. doi:10.1111/ijd.70557

4. Liu Z. A Holistic Skin Management Approach of CTMP Improved Skin Texture in Patient With Acne Scarring: A Case Report. Clin Case Rep. 2026;14(7):e72924. Published 2026 Jul 3. doi:10.1002/ccr3.72924

5. Chen YW, Chen YH, Yen TH, et al. Achieving Targeted Combined Endpoints in Patients With Atopic Dermatitis: A Real-World Study. J Dermatol. Published online July 3, 2026. doi:10.1111/1346-8138.70369